IL1B and neoplasm: As such, the improved chemosensitivity associated with NLR attenuation in our preclinical models suggest that combining chemotherapy with therapeutic strategies to mitigate neutrophil-stromal-tumor cell IL-1β/IL-6/STAT-3 signaling in PDAC patients may be advantageous.